Thank you all for coming. It's the third day, I lose track, of the Jefferies Healthcare Conference here in London. My name's Ben Jackson. I'm one of the European Biopharma analysts here at Jefferies. It's a pleasure today to be joined by the team at Pharming. We've got Kenneth, Leverne, Michael, all here to talk us through kind of the story, what we're looking forward to in the coming 12, 18 months, maybe a little bit longer. I'm excited to dig into it, but perhaps if we start, Kenneth, on your side, do you want to just give a few intro remarks to how things have been progressing recently, and then we'll dive right in with the Q&A?
No, absolutely, and thanks for having us. Seeing it was a great pleasure to have the opportunity to update everyone on the Pharming story. We've had a really good, strong start to the second half of the year with the strong performance in the third quarter, launching into additional markets internationally, and kind of have come in with strong confidence to the full-year performance in the fourth quarter. More specifically, for those of you that are familiar with us, on the RUCONEST side, we have stabilized the demand. We have returned to growth in revenue terms in the third quarter. On the Joenja side, we have continued strong growth, but we launched in Germany in the month of July. In Japan in August, we got pediatric approval, high dose in the U.S. in September, and we have kind of two important phase II readouts in the fourth quarter.
Both from a financial and non-financial point of view. We did announce a leadership transition by the end of September, and on an interim basis, Leverne, that was joining us as Chief Commercial Officer, 1st of January, and I joined as CFO last year in October, were tasked by the board as co-CEOs while we go through this transition. To tackle upfront, there are no changes related to the overall strategy of the company. We continue to work hard to become a global leading rare disease company. We are refining a little bit on the execution, so the how to get there. In the short term, absolutely no changes to our focus, our commitments, and also not related to anything in our pipeline.
Perhaps just last but least, we're dividing in our capacities as co-CEOs, where Leverne is taking care of all the patient-focused activities, and I'm overseeing on the corporate function side.
Brilliant. So look, the question I'm going to ask straight off the bat there around co-CEOs, talk to us about how you split the responsibilities. How do you divide those?
Yeah, and perhaps I will ask Leverne to talk, if you wouldn't mind, on the split and the areas she oversees.
No, for sure. So I'm responsible for all the patient-focused functions, which includes commercial, as Kenneth mentioned, as well as the global medical affairs, clinical development, and then manufacturing and supply chain. All the decisions, to Kenneth's point, strategy is clear, we persist, and we're making good progress.
Yeah, and the other functions, don't have to list all of them, but also including our continued strong efforts on scouting for and assessing opportunities in the BD and M&A space remains absolutely unchanged. And the board has given us the direction of saying, "Execute and don't pause, don't slow down. Just because we're in transition, we know what we have to do.
And I guess one of those things you are now executing on is that pediatric launch for Joenja in the U.S. Do you want to talk a little bit about how that is going, how we should think about that in terms of uptake of patients, and how important is that to the overall Joenja growth longer term?
No, for sure. So, you correctly said we got approval September 11th in the U.S. for the high-dose Joenja and APDS, and we started shipping in October. So, launch is going really, really well. We have managed to convert all of our early access program patients to reimbursed patients, and we started shipping those. We have guided in the earnings call that we anticipate approximately 15 to 20 new incremental pediatric-only patients that we will add in Q4. And that is on top of the 136 patients on therapy that we ended Q3 with. So a few important signals that we have seen. So APDS is a genetic condition, so as physicians now finally have an approved therapy, testing has increased. We have seen some important movements in patient identification as the quarter has evolved. So a bolus of patients in the fourth quarter and great momentum so far.
Got it. And then another leg of the story is obviously the international rollout as well. So what are the key milestones we are looking at in terms of getting Joenja ex-U.S. in terms of launches?
Great. Yeah. So Germany rolled into launch in July, right? And a really, really positive start. Two converted same, all our early access programs to funded patients. We have shipped those. Japan, we launched in August. We started shipping our first funded patients, which has been really, really encouraging. And we are making steady progress on formulary listing hospital by hospital. And so we are seeing the momentum there now manifesting in Japan. When you look at number of patients on therapy in Q3, 75 patients on therapy ex-U.S., of which 30 comes from these launch markets, so the U.K. included, so U.K., Germany, Japan. And the remaining come from other markets where we have sort of funding mechanisms or paid funding mechanisms in place. So, a really impressive sort of first quarter with these launches.
Now going into 2027 and into Q4, continued momentum on formulary listing, continued adoption and conversion into paid patients. As you look into the second half of next year, we are continuing our reimbursement and pricing efforts. Two markets in particular we look forward to launch, Australia in the second half of next year and Italy in the second half next year.
How do these markets, from your perspective, differ from the U.S. market in terms of hurdles or challenges to actually get the drug to have broad access and to get to the patients that need the drug? Is it more challenging internationally?
When you say access, I will sort of break it down into two things, right? There is pricing coverage or reimbursement. In every market that we have engaged in, so the U.K., Germany, Japan, we have been reasonably extremely successful actually to secure favorable pricing.
Yeah
And access for patients, right? The groundwork on getting formulary listing hospital by hospital, getting physician adoption essentially office by office, fundamentally different to the U.S. where you have concentrated center of excellences and concentrated physicians that treat APDS. Ex-U.S. somewhat different, right? Working additionally on referral pathways, working additionally on getting patients to treating physicians. That is a little of the lag that you see in adoption and makes it fundamentally different to the U.S.
Looking forward, we have some opportunities making themselves apparent in CVID and PID. If we take the latter first, since we have already seen the data for PIDs for Joenja, what is the key learnings from that data presentation? How consistent were those data with what you have seen in APDS, and how much confidence does that bring that there is a broader patient opportunity here for this asset?
For sure. Michael can jump in too. What gives us confidence that the mechanism of Joenja is really relevant is we have now proven in APDS that we have had substantial improvements in lymphoproliferation as we have seen in lymph node size, spleen size. We saw that in genetic PID studies. We have seen improvements in other domains, other organ systems, so lungs, liver, and in the blood, right? As we look at the second CVID study that is set to read out before the end of November, we are looking for consistencies in these domains. What is clinically meaningful? Clinically meaningful will be consistent improvements in lymphoproliferation. The second piece is consistent improvements in other organ domains.
Yep.
Patients improving across multiple of these. When I look at the profile of the patients enrolled in the second CVID study, two things stand out to me, right? We say these patients have CVID with immune dysregulation, so one way to think about it. In addition, they have APDS-like manifestations. So they already have a shared biology with APDS patients.
Yeah.
They already have a symptomology that almost mimics APDS patients. When you looked at the first genetic PID study readout, nine out of 13 of those patients with genetic PIDs also had a diagnosis of CVID. Regardless, with or without a genetic cause, we look forward to prove that we'll see consistent responses in these domains.
Yeah.
Yeah. The one thing I would add is, the data was really nice in the genetic PID study, where nine of 13 did have a CVID diagnosis. But I would point out that spleen volume, there was 11 patients that had enlarged spleen and evaluable large spleen. 10 of 11 had reductions, and also four of 11 patients had reductions in index lymph node size. The lung data was really strong, and I think especially surprising after only 20 weeks. There was a DLCO, which is a measure of lung gas exchange, improved by 8% in seven patients, and there was also CT scans showing improvement in interstitial lung disease. Really happy with that, and I think what really mattered most in that trial was not just the measures on any one of those measures, but really the breadth of response across multiple organ systems. We're really pleased with that.
I guess adding the final piece to the puzzle, I guess, going into the CVID readout is thinking about the non-genetically defined patients is kind of the big question that we have certainly on our side. What gives you confidence that those patients should respond? What data have we seen so far to support it? Ultimately, therefore, how confident are you walking into that data set?
Yeah.
Yeah. I mean, as Leverne mentioned, nine of the 13. I think first of all, let's take a step back to APDS. APDS is a monogenic form of CVID, so we do have that data with strong experience in the market. The genetic PID study, nine of 13 of those patients had an actual CVID diagnosis. That gives us confidence that the PI3K delta mechanism is relevant in the broader CVID population. Like you said, we do have to see what the data's going to show, but I think that gives us confidence. We also do have some expanded access experience with six patients, six CVID patients that were on leniolisib for, I think it was a median of a year and a half that was reported at the CIS conference back in May that was also quite positive.
The one that we don't touch on much now is VUS, because I feel like we've got other opportunities coming forward. Could you remind us what's going on there, what kind of opportunity that presents, and could we see something move with that soon?
Indeed. VUS in APDS remains, it remains an important diagnostic challenge, right? It's complex. It's really tough. We continue to work with various academic institutions and key opinion leaders to generate additional data that could potentially help reclassify some of these VUS patients. When I talk about the growth trajectory of APDS today, our outlook excludes any potential VUS reclassifications, right? While we continue to refine the science on that, we still remain extremely confident that the growth catalyst in the short term, pediatric indication in the short term, both high dose and then low dose in January, if it bears out well, in addition to international expansion now CVID, which is potentially a blockbuster opportunity, still sets Joenja on a really positive track. More to follow on the VUS work.
But like I said, for the moment, we've excluded that from our outlook, and still really important catalyst for Joenja.
Very reasonable. If we shift on to RUCONEST then. What surprised us, I think, at the 3Q results and the pre-announcement we had is that stabilization in RUCONEST after we had a competitor entry. Perhaps you could talk about what's gone on to enable that stabilization in volumes and how you think, therefore, that plays out going into next year when we have to think of another. So two questions in one, but
I know.
We can do them separately.
Yeah, no. I like the way you said, surprised everyone. I mean, what was really relevant in the HAE market, particularly the on-demand market, was the new entrance of sebetralstat July last year in the U.S. Fundamentally, it was the first on-demand, the new on-demand treatment in over 12 years.
Yeah.
Right. I think folks sort of struggle to how you predict impact, but what we've certainly seen after four quarters of impact is, as you said, we've returned our demand to a near pre-competitive level. We've stabilized demand. What does that tell us? We've retained more than 90% of our active patient base over competitive impact. We absorbed most of the impact in the first, second quarters, post-competitive impact, and then started building back in the third quarter, which is the results that you see in our Q3 results. Why is that surprising? RUCONEST fundamentally is not a first-line therapy, right? It's an intravenous therapy for high-burden patients that suffer frequent attacks, that suffer severe attacks, that need a fast, reliable intravenous therapy.
Yeah
in these moments of crisis, right? We've seen a remarkable resilience in this population, right, that wouldn't ordinarily just switch a therapy simply because it's new, but has stuck with RUCONEST pretty resiliently through this time period. While we've seen some trial and we've seen some adoption of sebetralstat over the last year, these high-burden patients have been remarkably resilient, right? What does it tell us? RUCONEST is a cornerstone in HAE, regardless of how we anticipate the competitive environment to evolve. The other really important thing that we've seen in the last year, because in addition to a new on-demand competitor, there's been two new prophylactic entrants right now. I think there was an assumption across the market that prophies will fundamentally impact the on-demand market. That is not what we've seen with RUCONEST, right?
Again, these high-burden, severe patients that have breakthrough despite using garadacimab, despite using donidalorsen, still having breakthrough, and we've seen no contraction in their value utilization. Looking forward, how do I see this product in this market? These severe patients, unfortunately, are always at risk of breakthrough, right? Having breakthrough on-demand, breakthrough attacks that do require a reliable, fast onset intravenous therapy. Again, that resilience of this population, we anticipate that to persist. The second oral competitor may come next year in the U.S., and I think about that in two different ways. It is the second oral competitor. The good thing for the first mover in this space is a fair number of patients have tried an oral over the last year. The big question is, how many new patients will try a second oral? First question.
The second piece is, the second oral that will come to market potentially in Q2 is a known mechanism of action. It's based on icatibant, a known mechanism of action. In our case, a very high proportion of our patients have failed icatibant before, right? Again, RUCONEST, not a first-line therapy. Many of our patients have tried icatibant and failed. The question for us that we're working through is, how would this oral version of icatibant impact a group of patients that are high burden in cases where they failed other therapies? We anticipate impact. We are expecting folks to try it first quarter, second quarter, similar pattern we've seen with sebetralstat. But we are really confident that that resilient base of high-burden patients that may have tried and failed therapies before will persist.
Got it. And perhaps less of a clinical question here, but remind us about the inventory movements that we see in a yearly basis with RUCONEST and how these are playing into the fourth quarter of the year as well. I think it's an important thing to touch on.
I think we have seasonality. We know that the specialty pharmacies in the U.S. are building inventory in the second half of the year.
Yeah.
Partly in anticipation of demand trends, partly in anticipation of price movements or price increases January 1st. That's very normal. What we saw in the beginning of this year for those two reasons was a drawdown, but the comparators of Q1 of 2025 was skewed because 2025, we didn't have a normal year of seasonality. 2026 is a normal year. So the drawdown in the beginning of the year, we have seen already partly in Q3 and also some in Q4, that the inventory is being built. So we are in a normal year of seasonality, which is also going to create a normalized basis for comparison as we head into next year. So everything is normal, back to normal, but it wasn't normal in 2025.
Yeah. Longer term then, how do you guys think about the trajectory for RUCONEST? How do you build those into your plans for when you're doing long-term financial forecasting and budgeting?
So if I start by saying that, we define RUCONEST as a durable cash engine. The profitability level is attractive, the cash inflow is significant, and it is helping us basically to self-fund all the activities we have related to current pipeline assets. That we believe we will maintain. We think the growth will be relatively modest in the lower single-digit growth as a combination of continued price increase and some demand movement. But it will continue to have a small. But we do not define it as a growth engine for the company, but as a cash engine.
Yeah. I will add two things in addition to that, right? The first one is, what is really cemented over the last year for me is the positioning of RUCONEST. Who are the patients that really need it? Who are the physicians who are treating very severe patients, that tend to have failed other therapies? And there is a resilience there, as I said before, right? I think the other piece that is also important is we continue to add new patients, right? Because patients are failing previous therapies. We have restarts because patients are failing previous therapies. So to Kenneth's point, the stable core of RUCONEST, and the stable revenue that we rely on, we can predict into the future. Then finally, of course, it is a pretty difficult product to make, right?
So you sort of think about, do we anticipate generic impact or biosimilar impact? For the moment, it is a very complex manufacturing process, and we are really, really confident that there will be a high bar for entry for the product.
Yeah. We spend a lot of time talking about these two products, but it is not the only thing going on in the portfolio. We must touch on KL1333. So perhaps you can remind us what are the next big milestones for this study in terms of learning more, and what drives the confidence that that acquisition was the correct thing to do for Pharming?
Yeah, I mean, napazimone or KL1333 is unique. It's a potential first disease-modifying therapy for mitochondrial DNA-driven primary mitochondrial disease. So it's unique. It normalizes the NAD+/NADH ratio and corrects mitochondrial function. We now have, in the pivotal FALCON clinical study, we have 50 clinical sites now operational and enrolling patients. We expect to enroll 145 of the 180 patients in the study by the end of this year, and to complete enrollment in the first half of 2027, during the first half of 2027. Then it's 48 weeks to readout, so about a year later, so first half 2028, we'll have the That's the timing for the top line readout in that study. I think that's really the next updates, is the completion enrollment and the data readout.
What's notable about the trial design in terms of positioning in this disease, ultimately? What's important?
Yeah, I think what's unique is that we have selected very patient-relevant endpoints that are supported by the FDA. The two primary endpoints are fatigue, where patients really have debilitating fatigue here that affects their life, and a sit-to-stand test as a measure of muscle weakness. So, I think those are two alternate primary endpoints. We need to have success in one of those endpoints to support approval. Importantly, both of those endpoints cleared futility in the interim analysis. That was sort of a big motivator for us to acquire Abliva, who's the innovator of the asset.
Yeah. To what extent is the commercial organization already set up when the time hopefully comes that this asset needs to be launched?
Indeed. I am excited because this asset has a unique opportunity to address, as Michael said, debilitating fatigue, profound muscle weakness in these patients. What we see in terms of the archetype and where those patients are, they are in very concentrated center of excellences that treat primary mitochondrial disease. Our capabilities that we have proven with Joenja around both patient identification, commercializing in these centers of excellence, securing pricing and reimbursement for these rare diseases, the patient services programs that we have in place across both RUCONEST and Joenja, all of those commercial capabilities easily scalable here. We have launched in other countries, so our international expansion plan is a question of scaling the success that we have had today. I think the last piece from an investment perspective, we have enough cash on hand, and Kenneth can speak to that, to fund our pre-launch activities.
Really excited for what this compound could mean in PMD.
The natural next question, I guess, then goes on to cash on hand. Is there interest in BD more broadly? What would you be looking for if you potentially were interested, and where would you go with that? Interesting to hear any comment.
No, absolutely. I mean, we are absolutely interested, and as much, if not more than before.
Yeah.
It is an integrated part of our strategy. We have a dedicated team that is working on identifying opportunities, and we are looking at both opportunities to strengthen the pipeline, but potentially also to add to the portfolio over time. At the end of September, we had about $190 million of cash on our balance sheet. That is probably in the range of $100 million-$120 million excess cash that could be taken directly to fund. Together with the cash that we are generating every year, we are sufficiently covered to also cover all the cost of the pipeline activities that we already have. Of course, we are kind of, as any other company, preparing in terms of potential capital structure updates to accommodate also if it would go above and we would need to take financing of different kinds. It is an integrated part of our strategy. We want to do it.
We are working actively on that, and we are constantly in dialogue or assessing concrete opportunities also.
Got it.
Yeah.
Makes sense. Look, in the last 30 seconds then, broad question, no pressure to dig something out, but what do you think people are most missing about the story at this point then? We have touched on a lot. Is there anything we should have spoken about a little bit more?
No, I do not think there is anything we should have spoken about more. I think that our job is to continue to make people understand and be most comfortable with the pipeline, which is holding two assets that have significant opportunities each beyond $1 billion of peak sales.
Yeah.
The fact that we historically have been more defined as a company because of RUCONEST, that change in narrative, I think, has come nicely across in the chat here this morning. And that is what we continue, the three of us, to focus on every time we speak to people like yourself and the wider audience.
Got it. Thank you for your time.
Thank you so much.
Lots to look forward to, excited for it. If anyone has any questions, please do feel free to reach out to myself or the team.
Tha`nks for having us.
Thank you.
Thanks, Ben.